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Role of Imaging in Cardiac Stem Cell Therapy
Saskia L. M. A. Beeres, MD,* Frank M. Bengel, MD,† Jozef Bartunek, MD,‡ Douwe E. Atsma, MD,*
Jonathan M. Hill, MD,§ Marc Vanderheyden, MD,‡ Martin Penicka, MD, Martin J. Schalij, MD,*
William Wijns, MD,‡ Jeroen J. Bax, MD*
Leiden, the Netherlands; Baltimore, Maryland; Aalst, Belgium; London, United Kingdom;
and Prague, Czech Republic
Stem cell therapy has emerged as a potential therapeutic option for cell death-related heart diseases. Preclinical
and a number of early phase human studies suggested that cell therapy may augment perfusion and increase
myocardial contractility. The rapid translation into clinical trials has left many issues unresolved, and empha-
sizes the need for specific techniques to visualize the mechanisms involved. Furthermore, the clinical efficacy of
cell therapy remains to be proven. Imaging allows for in vivo tracking of cells and can provide a better under-
standing in the evaluation of the functional effects of cell-based therapies. In this review, a summary of the
most promising imaging techniques for cell tracking is provided. Among these are direct labeling of cells with
super-paramagnetic agents, radionuclides, and the use of reporter genes for imaging of transplanted cells. In
addition, a comprehensive summary is provided of the currently available studies investigating a cell
therapy-related effect on left ventricular function, myocardial perfusion, scar tissue, and myocardial
viability. (J Am Coll Cardiol 2007;49:1137–48) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.072a
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atem cell transplantation is being widely investigated as a
otential therapy for cell death-related heart diseases (1).
everal cell types, including embryonic stem cells (2),
keletal myoblasts (3,4), bone marrow-derived cells (5–7), or
ardiac resident stem cells (8,9), are being tested, and
reclinical studies have shown the potential of various
pproaches to repair acutely or chronically damaged
yocardium.
In some experimental settings, transplantation of stem or
rogenitor cells after myocardial infarction reduces scar
ormation and fibrosis, and preserves cardiac function.
oreover, different subsets of progenitor cells were shown
o augment perfusion. Both observations may be related to
direct physical effect (differentiation of progenitor cells to
ndothelial cells, smooth muscle cells, and cardiomyocytes)
nd/or to the release of paracrine factors by progenitor cells,
hich prevent apoptosis of cardiomyocytes, modulate scar
evelopment, or promote angiogenesis (1).
On the basis of these encouraging preclinical studies,
here is a growing number of early phase human studies that
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006, accepted October 23, 2006.im to demonstrate the feasibility and potential efficacy of
ell-based therapies in the clinical setting (10–35). This
apid translation into clinical studies has left a lot of
uestions concerning cell therapy unanswered. For example,
he optimal cell type, the number of cells to be delivered, the
ost suitable route for cell delivery, and the optimal time
oint for cell delivery after myocardial infarction are un-
nown. Furthermore, the biodistribution of the therapeutic
ells after delivery and the specific mechanism by which
herapeutic cells contribute to functional improvement re-
ain to be investigated. Imaging is crucial for in vivo
racking of cells and better understanding and evaluation
f the effects of cell therapy. In this review, we have
ttempted to summarize the available evidence on imaging
f cell therapy.
ell Tracking by Use of Noninvasive Imaging
he ideal imaging modality should provide integrated
nformation related to the entire process of cell engraftment,
urvival, and functional outcome. Clinically established
arameters of noninvasive imaging, such as contractile
unction, perfusion, and viability of the myocardium, do not
rovide direct visualization of transplanted cells, their biol-
gy or function. Thus, a number of contrast agents and
etectors for noninvasive, repeatable visualization of thera-
eutic cells in vivo have been pursued (36). Such imaging
pproaches may not only refine the understanding of ther-
peutic mechanisms in preclinical studies but may also have
irect clinical applications. Most of the available cellular
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Imaging of Stem Cell Therapy March 20, 2007:1137–48molecular imaging techniques
are also applicable in humans,
and therefore may facilitate rapid
translation of cell-based thera-
pies into clinical practice. Table 1
and Figure 1 summarize labeling
strategies for in vivo surveillance
and tracking of various cell pop-
ulations.
Radionuclide technology and
magnetic resonance imaging
(MRI) are best suited to meet
such broad objective thanks to
their resolution and clinical ap-
plicability, with MRI having
some advantages in terms of spa-
tial resolution (Table 2). Cells
can be labeled directly with
super-paramagnetic iron oxide
agents or radionuclides before
heir application for subsequent in vivo visualization of their
istribution. Additionally, genetic labeling with reporter
enes that can be traced with imaging probes has been
ntroduced, which will allow for repeatable tracking of
ellular and subcellular function over a longer period of
ime. The use of non-invasive imaging modalities in pre-
linical cell therapy studies revealed key aspects of cell
iology that will not be observed by other approaches except
or histologic analysis. In particular, the ability to dynami-
ally follow cell trafficking and survival over longer periods
f time contributed to the understanding of the potential
echanism of benefit.
irect labeling of cells using magnetic resonance agents.
agnetic resonance imaging has become a key surrogate
nd point to demonstrate efficacy in early phase, small-sized
tudies (37). Magnetic resonance imaging can provide
etailed morphologic and functional information and,
herefore, seems ideally suited to integrate efficacy assess-
ents with the capability for cell tracking. The potential for
ssessing engraftment of therapeutic cells was quickly real-
zed, and investigations are now focusing on refining con-
rast agents to ensure maximum signal for minimum label-
echniques for In Vivo Imaging of Labeled Transplanted Cells
Table 1 Techniques for In Vivo Imaging of Labeled Transplante
Method Agent A
MRI SPIO High resolution
No radiation
Nuclear (direct labeling) In-111 oxin High sensitivity
Tc-99m HMPAO High translational ca
F18-FDG
Nuclear (reporter genes) Various reporter genes/probes High biologic specifi
Studies of subcellula
Optical Luciferase/luciferin High sensitivity
NIRF probes No radiation
Abbreviations
and Acronyms
CT  computed
tomography
FDG  fluorodeoxyglucose
HMPAO  exametazime
LV  left
ventricle/ventricular
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
MRI  magnetic resonance
imaging
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomography18-FDG  fluorodeoxyglucose; HMPAO  exametazime; In  indium; MRI  magnetic resonance imagng. Initial animal model studies using micron scale particles
38,39) or nanoparticles of iron oxide (40,41) showed the
otential for non-toxic labeling of hematopoietic bone
arrow-derived and mesenchymal stem cell populations
ithout affecting their transdifferentiation capacity. In the
ardiovascular setting, this cell labeling technology was
oupled with direct delivery methods using endomyocardial
njections, demonstrating that transplanted cells could be
maged shortly after delivery with a high degree of spatial
esolution using MRI (40) (Fig. 2). Iron oxide labeling can
lso be used to track smaller numbers of cells in homing
xperiments allowing for in vivo identification of mesenchy-
al stem cells that migrated to infarcted myocardium after
ntravenous administration (41). Yet, in the studies de-
cribed in the preceding text, the lowest detectable number
f cells was 105 with the use of conventional MRI scanners
ithout any sequence modification. This threshold of de-
ection can be lowered using high-field magnets (11.7-T)
uch that single cells containing a single iron particle can be
etected and tracked (42).
There are potential theoretical disadvantages to the use of
agnetic labeling. Most importantly, the imaging signal is
ot directly linked with cell viability. There is a risk for
elease of iron oxide after cell death and its accumulation in
ystander cells confounding any quantitative assessment of
ell trafficking. In addition, cell division can dilute the
agnetic label within only a few cell divisions. Novel direct
abeling techniques like Clio-tat peptides (43) or magnetic
elaxation switches (44) are under development in preclin-
cal studies and could help overcome some of these limita-
ions in the future. Despite minimal effect of iron oxide
articles on in vitro proliferative capacity and cell viability
38), there are recent data raising concern about the impact
n the differentiation capacity of mesenchymal stem cells
long a chondrogenic differentiation pathway (45). On the
ther hand, this effect may be compound specific, because
he 2 Food and Drug Administration-approved iron oxide-
ased agents affect neither hematopoietic nor mesenchymal
tem cell function or differentiation capacity (46). Before
linical application, future work is required to investigate
he effect of iron-labeling on stem cell proliferation and
ifferentiation.
ls
ges Disadvantages
Low sensitivity
Signal may not reflect viable cells
Radiation exposure to individual
Potential effects of radiation on therapeutic cells
Decay of radioactivity, signal may not reflect viable cells
gnal linked to viability) Limited robustness of weak signal
ts (differentiation) Concerns related to genetic modification
At present limited to small animals
Not clinically applicabled Cel
dvanta
pacity
city (si
r evening; NIRF  near infrared fluorescent; SPIO  super-paramagnetic iron oxide; Tc  technetium.
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March 20, 2007:1137–48 Imaging of Stem Cell Therapyirect labeling of cells using radionuclides. Direct label-
ng of cells with radionuclides provides the advantage of a
ower background signal as compared with MRI. However,
igher sensitivity is achieved at the cost of lower spatial
esolution. Various clinically applicable radionuclides have
een used, based on previously established protocols for
eukocyte or thrombocyte scintigraphy. Direct labeling with
adionuclides appears highly informative for clinical studies
ddressing homing and biodistribution after cell injection.
ndium (In)-111–labeled endothelial and hematopoietic
rogenitor cells were found to accumulate in infarcted rat
yocardium after intraventricular injection (Fig. 3), but the
Figure 1 Approaches for Cell Tracking by Noninvasive Imaging
Cells are labeled directly for magnetic resonance imaging (MRI), positron emission
a reporter gene for subsequent reporter-gene imaging using either of the technique
particle; SPIO  super-paramagnetic iron oxide; Tc  technetium.
uclear Imaging and MRIn Cardiac Stem Cell Therapy
Table 2 Nuclear Imaging and MRIin Cardiac Stem Cell Therapy
Process MRI Nuclear Imaging
Cell homing/distribution  
Cell survival ? /
Cell integration/differentiation ? Potential with reporter
gene technology
Molecular effects  
Structural tissue and organ
remodeling
 
LV regional and global function  /
Perfusion/metabolism  cV  left ventricular; MRI  magnetic resonance imaging.verall radioactivity in the heart was only around 4.7% of
he injected dose (47). These data suggest that only a small
umber of cells ultimately home to injured myocardium, but
hey also corroborate the high sensitivity of the nuclear
maging technique. In another study using In-111–labeled
esenchymal stem cells in pigs, accumulation in the lungs
as observed early after intravenous injection, which was
ound to obscure assessment of myocardial cell trafficking
48). This observation was confirmed in rats by another
roup, using technetium (Tc)-99m exametazime (HMPAO)
or labeling of bone marrow-derived mesenchymal stem
ells and observing entrapment of the donor cells in the
ungs (49). More recently, homing of In-111–labeled mes-
nchymal stem cells to infarcted myocardium was success-
ully visualized in a dog model using single-photon emission
omputed tomography (SPECT)-CT (41). Finally, the
ositron emission tomography (PET) tracer F18-
uorodeoxyglucose (F18-FDG) has been used for labeling
nd imaging of bone marrow cells in humans. Myocardial
ccumulation of cells was demonstrated after intracoronary
nfusion, but not after intravenous delivery. With immuno-
agnetically enriched CD34-positive cells, 14% to 39% of
otal injected radioactivity was detected in infarcted myo-
ardium after intracoronary injections, preferentially in the
order zone (50). Other data indicate that radiolabeling
graphy (PET), single-photon emission computed tomography (SPECT), or with
-FDG  fluorodeoxyglucose; HMPAO  exametazime; IFP  iron fluorescenttomo
s. F18ould be used to assess early kinetics after cell injection.
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Imaging of Stem Cell Therapy March 20, 2007:1137–48c-99m-HMPAO–labeling of mononuclear cells indicated
hat cardiac engraftment of cells is a dynamic process: the
adioactivity uptake by the heart was 5% at 2 h and 1% at
8 h after transcoronary cell transplantation in a patient
ith acute myocardial infarction (51). These data support
he translational potential of nuclear imaging to guide cell
herapy approaches from preclinical to clinical applications
nd to provide mechanistic information in applications like
ntracoronary administration with higher sensitivity than
RI. Future work should aim to prolong the half-life time
f radioisotopes in order to prevent loss of the imaging
ignal within a few days.
eporter genes for cardiovascular cell imaging. The
sefulness of reporter genes for imaging of gene transfer to
he myocardium has been established recently (52). This
rinciple may be expanded to imaging of cell-based thera-
ies. A reporter gene of choice can be transferred to cells for
enetic labeling, before their in vivo administration. After
pplication, cells can then be detected by an intravenously
dministered, radio-labeled or optical reporter probe, which
s specific for the reporter gene and which accumulates
Figure 2 Magnetic Resonance Imaging Labeling Using Combine
Fluorescent green component of iron-fluorophore-labeled porcine mesenchymal ste
panel imaged using Nomarski optics (middle). Hemotoxylin/eosin stain of same p
axis slice of a porcine left ventricle after anteroapical intramyocardial injection of i
myocardial border (arrows) is the signal void created by the iron-labeled cells.olely in the transduced therapeutic cells (Fig. 4). Because tccumulation of the reporter probe requires expression of
he reporter gene and activity of the reporter-gene product,
he imaging signal will be dependent on viability of the
herapeutic cells. This is in contrast with direct “passive”
abeling techniques and provides a more specific readout.
dditionally, imaging can be performed repeatedly and is
ot limited by radioactive decay of the initial label load.
bservation of genetically labeled cells is thus possible over
long period of time, and may only be limited by epigenetic
ilencing (53).
Proof of principle for imaging of genetically labeled cells
as obtained using rat cardiomyoblasts, which were infected
x vivo with adenovirus carrying the HSV1-sr39tk and
uciferase reporter genes. Cell-specific in vivo optical and
icro-PET imaging was feasible for up to 2 weeks after
irect injection of cells into the myocardium of nude rats.
or optical imaging, 5  105 cells were detectable, while
ET images were obtained using 3  106 cells (54).
ubsequent preclinical studies used reporter-gene labeling
o demonstrate usefulness of novel intramyocardial injection
echniques and assess cell survival, proliferation, and migra-
odality Imaging Agent
s delivered by intramyocardial injection with nuclei stained blue (left). Same
ith iron-labeled cells appearing brown (right). Magnetic resonance imaging long-
orophore-labeled mesenchymal stem cells (bottom). The black area on the endo-d M
m cell
anel w
ron-fluion over a longer period of time (55,56).
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March 20, 2007:1137–48 Imaging of Stem Cell TherapyImportantly, genetic labeling also holds promise to pro-
ide insights into subcellular mechanisms that take place
ithin therapeutic cells. Reporter genes may be expressed
nder control of restrictive promoters that are sensitive to
ertain endogenous molecules. Despite bearing a conceptual
romise, the use of reporter-gene imaging to monitor cell
ransplantation is still limited to animal model studies. In
rder to proceed from bench to bedside, further work is
equired to develop nonimmunogenic probes, improve
ransfection stability, and reduce the interference of trans-
ection with the cell function and desired molecular effect.
trength of the imaging signal is critical, and additional
ork is necessary to establish a robust approach for cell
isualization that is also practical for use in the clinical
etting.
maging to Evalute
unctional Effects of Cell Therapy
maging may be particularly helpful in evaluating the
unctional effects of cell therapy. The various clinical studies
ave mainly focused on detection of differences in left
entricular (LV) function, myocardial perfusion, infarct size,
Figure 3 Tracking of In-111–Labeled Endothelial Progenitor Cel
After experimental myocardial infarction, 106 indium (In)-111–labeled cells were in
images of the whole animal, along with magnification of the cardiac area. Significant cnd myocardial viability. tV function. Table 3 summarizes the 17 available studies
including 10 or more patients) that have evaluated changes
n LV function after cell therapy. In total, 526 patients
nderwent cell therapy in these studies. Ten studies were
erformed in the setting of acute myocardial infarction, and
studies were performed in the setting of chronic ischemic
eart disease. Assessment of function was performed rang-
ng from 3 to 18 months after cell therapy.
Ten studies showed an improvement in LV ejection
raction (LVEF), indicating improved systolic function.
he majority of studies indicated small improvements in
VEF (range 2.9% to 9.3%), but Chen et al. (19) demon-
trated in 34 patients with acute myocardial infarction an
mprovement of 18%. Different techniques were used to
ssess LV function and volumes, including LV angiography,
-dimensional echocardiography, gated SPECT, radionu-
lide ventriculography, and MRI. The most accurate assess-
ent of LVEF and LV volumes is MRI, and Fernández-
vilés et al. (18) demonstrated an increase of 5.8% in LVEF
s assessed by MRI, whereas no improvement was seen in
ontrol patients. The global improvement of LVEF was
ainly related to an improvement of regional LV function
n the infarct zone, although improvement of function in
the Rat Heart
intramyocardially (left) or intravenously (right). Shown are planar scintigraphic
retention of cells in the heart is only identified after intramyocardial injection (arrow).ls in
jected
ardiache infarction border zone has also been reported.
Effect of Cell Therapy on LV Function and Volumes
Table 3 Effect of Cell Therapy on LV Function and Volumes
Study No. of Patients Setting/Study Design
Route of
Delivery Cell Type
Follow-Up
(Months) LVEF LVESV LVEDV
Regional
Contractility
Technique
Used
Strauer et al. (10) 10 vs. 10 control subjects AMI/observational, control  Intracoronary 2.8  107 BMC 3  2  1 Wall motion in
infarct zone
LV angiography
RNV
TOPCARE-AMI (11–13) 29 BMC
30 CPC
AMI/observational, control  Intracoronary 2.1  108 BMC
1.6  107 CPC
12 1(9.3%) 2  1 Wall motion in
infarct zone
LV angiography
Cine MRI
2D echo
BOOST (16,17) 30 vs. 30 control subjects AMI/randomized, sham  Intracoronary 2.4  109 BMC 18     Cine MRI
Fernández-Avilés et al. (18) 20 vs. 13 control subjects AMI/observational, control  Intracoronary 7.8  107 BMC 6 1(5.8%) 2  1 Wall motion in
infarct zone
Cine MRI
Chen et al. (19) 34 vs. 35 control subjects AMI/randomized, sham  Intracoronary 4.8–6.0  1010
BMC
6 1(18.0%) 2 2 1 Wall motion in
infarct zone
LV angiography
Bartunek et al. (20) 19 vs. 16 control subjects AMI/observational, control  Intracoronary 1.3  107 BMC 4 1(7.0%) 2  1 Wall motion LV angiography
Janssens et al. (21) 33 vs. 34 control subjects AMI/randomized, sham  Intracoronary 4.8  108 BMC 4     Cine MRI
REPAIR-AMI (22) 101 vs. 103 control
subjects
AMI/randomized, sham  Intracoronary 2.4  108 BMC 4 1(5.5%)   1 Wall motion in
infarct zone
LV angiography
ASTAMI (23) 50 vs. 50 control subjects AMI/randomized, sham  Intracoronary 6.8  107 BMC 6    NA Gated SPECT
Cine MRI
2D echo
TOPCARE-CHD (24) 28 BMC vs. 24 CPC vs. 23
control subjects
CMI/randomized, sham  Intracoronary 2.1  108 BMC
2.2  107 CPC
3 1(2.9%)   1 Wall motion in
infarct zone
LV angiography
IACT (25) 18 vs. 18 control subjects CMI/observational, control  Intracoronary 9  107 BMC 3 1(8.0%) NA NA 1 Wall motion in
infarct zone
LV angiography
Katritsis et al. (26) 11 vs. 11 control subjects CMI/observational, control  Intracoronary 2–4  106 BMC
and EPC
4    1 Wall motion 2D echo
RNV
Fuchs et al. (27,28) 27 AP/observational, control  Intramyocardial 7.8  107 BMC 3  NA NA  2D echo
Beeres et al. (29–31) 25 AP/observational, control  Intramyocardial 8.4  107 BMC 12 1(4.0%) 2  1 Wall motion Gated SPECT
Cine MRI
Perin et al. (32,33) 14 vs. 7 control subjects HF/observational, control  Intramyocardial 3  107 BMC 12  2 NA NA LV angiography
2D echo
Erbs et al. (34) 13 vs. 13 control subjects CTO/randomized, sham  Intracoronary 6.9  107 G-CSF-
mobilized cells
3 1(7.2%)   1 Wall motion Cine MRI
Gated SPECT
MAGIC (35) 10 vs. 17 control subjects AMI/CMI/randomized,
sham 
Intracoronary 1.5  109 G-CSF-
mobilized cells
6 1(6.4%) 2 NA NA Gated SPECT
2D echo
AMI acute myocardial infarction; AP angina pectoris; ASTAMI Evaluation of Treatment with Intracoronary Mononuclear Autologous Bone Marrow Cell Therapy Among Patients With Acute Anterior Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention;
BMC  bone marrow cells; BOOST  Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration; CMI  chronic myocardial infarction; CPC  circulating progenitor cell; CTO  chronic total occlusion; echo  echocardiography; EPC  endothelial progenitor cell; G-CSF 
granulocyte-colony-stimulating factor; HF heart failure; IACT Regeneration of Human Infarcted Heart Muscle by Intracoronary Autologous Bone Marrow Cell Transplantation in Chronic Coronary Artery Disease; LV left ventricular; LVEDV left ventricular end-diastolic volume; LVEF
 left ventricular ejection fraction; LVESV left ventricular end-systolic volume; MAGIC Effects of Intracoronary Infusion of Peripheral Blood Stem Cells Mobilized with Granulocyte Colony-Stimulating Factor on LV Systolic Function and Restenosis after Coronary Stenting in MI; MRI
magnetic resonance imaging; NA not available; REPAIR-AMI Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction; RNV radionuclid ventriculography; sham placebo-controlled; SPECT single-photon emission computed tomography;
TOPCARE-AMI  Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction; TOPCARE-CHD Transplantation of Progenitor Cells and Regeneration Enhancement in Congenital Heart Disease; 2D 2-dimensional.
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Route of
Delivery Cell Type
Follow-Up
(Months) Main Findings Technique Used
 Intracoronary 2.8  107 BMC 3 2 Perfusion defect Tl-201 SPECT (rest)
 Intracoronary 2.1  108 BMC 4 2 Perfusion defect Tl-201 SPECT (rest)
1.6  107 CPC 1 Coronary flow reserve Intracoronary Doppler
 Intracoronary 1.3  107 BMC 4 2 Perfusion defect Tc-99m sestamibi SPECT (rest)
Intracornary 4.8  108 BMC 4  Perfusion defect C-11 acetate PET (rest)
Intracoronary 9  107 BMC 3 2 Perfusion defect Tc-99m tetrofosmin SPECT (rest)
Intracoronary 2–4  106 BMC and EPC 4 2 Perfusion defect Tc-99m sestamibi SPECT (stress-rest)
Intramyocardial 7.8  107 BMC 3 1 Stress perfusion in
injected territories
Tl-201 SPECT (rest)
 Stress perfusion in
remote territories
Tc-99m sestamibi SPECT (stress)
Intramyocardial 8.4  107 BMC 12 2 Extent of ischemia Tc-99m tetrofosmin SPECT (stress-rest)
Intramyocardial 3  107 BMC 12  Perfusion defect Tc-99m sestamibi SPECT (stress-rest)
2 Extent of ischemia
Intracoronary 6.9  107 G-CSF-mobilized cells 3 1 Coronary flow reserve Intracoronary Doppler
 Intracoronary 1.5  109 G-CSF-mobilized cells 6 2 Perfusion defect Tl-201 SPECT (rest)
Tl-99m sestamibi SPECT (stress)
 Coronary flow reserve Intracoronary Doppler
P able 3.
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increase
in
F
of
6.7%
in
bone
m
arrow
cell
transfer
patients,
as
ared
w
ith
0.7%
in
controlsubjects
(p

0.01).H
ow
-
at
18
m
onths,the
L
V
E
F
change
w
as
not
significantly
entbetw
een
the
2
groups(
5.9%
vs.
3.1%
;p

N
S).
sis
of
the
tim
e
course
of
L
V
E
F
im
provem
ent,
how
-
revealed
a
significantly
faster
recovery
ofL
V
E
F
in
the
m
arrow
celltransfer
patients
than
in
controlpatients
0.01)
(17).
ardialperfusion.
A
totalof11
studies(including
239
ts)
evaluated
the
effect
of
cell
therapy
on
perfusion
ffect of Cell Therapy on Myocardial Perfusion
Table 4 Effect of Cell Therapy on Myocardial Perfusion
Study No. of Patients Setting/Study Design
Strauer et al. (10) 10 vs. 10 control subjects AMI/observational, control
TOPCARE-AMI (11–15) 29 BMC AMI/observational, control
30 CPC
Bartunek et al. (20) 19 vs. 16 control subjects AMI/observational, control
Janssens et al. (21) 33 vs. 34 control subjects AMI/randomized, sham 
IACT (25) 18 vs. 18 control subjects CMI/observational, control 
Katritsis et al. (26) 11 vs. 11 control subjects CMI/observational, control 
Fuchs et al. (27,28) 27 AP/observational, control 
Beeres et al. (29–31) 25 AP/observational, control 
Perin et al. (32,33) 14 vs. 7 control subjects HF/observational, control 
Erbs et al. (34) 13 vs. 13 control subjects CTO/randomized, sham 
MAGIC (35) 10 vs. 17 control subjects AMI/CMI/randomized, sham
ET  positron emission tomography; Tc  technetium; Tl  thallium; other abbreviations as in T
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Imaging of Stem Cell Therapy March 20, 2007:1137–48cute myocardial infarction, 3 studies in patients with
hronic infarction, and 3 studies in patients with stress-
nduced ischemia. Assessment of perfusion was performed
anging from 3 to 12 months after therapy. The clinically
vailable tools for assessment of myocardial perfusion in-
lude nuclear imaging with PET or SPECT, MRI using
rst-pass perfusion, or myocardial contrast echocardiogra-
hy. In addition, coronary blood flow can invasively be
ssessed using the Doppler flow wire at rest and during
harmacologic stress. Subsequent calculation of the cor-
nary flow reserve provides insight into the integrity of
oth the epicardial conduit arteries and the distal micro-
ascular bed.
In 9 of 11 currently available studies, SPECT was used,
nd only Janssens et al. (21) used PET to evaluate the effect
f cell therapy on perfusion. It should be emphasized,
owever, that only PET permits absolute quantification of
yocardial perfusion, whereas SPECT provides informa-
ion on relative changes in tracer uptake.
The majority (10 of 11) of studies demonstrated some
ffect of cell therapy on perfusion. For example, Bartunek
t al. (20), using resting Tc-99m sestamibi SPECT, dem-
nstrated a decrease in resting perfusion defect size at 4
onths. Conversely, defect size did not change in control
atients. Similar results were reported by other groups. Of
ote, the only study with PET could not demonstrate an
ncrease in perfusion (21).
The majority of the studies evaluated only resting perfu-
ion, but few studies evaluated both rest and stress perfusion
ith SPECT. Beeres et al. (31) demonstrated in patients
ith refractory angina a significant decrease in the number
f segments with stress-inducible ischemia. A patient
Figure 5 Technetium-99m Tetrofosmin SPECT Polar Maps at B
Technetium-99m tetrofosmin single-photon emission computed tomography polar m
line (left). Three months after intramyocardial injection of autologous bone-marrow
emia (middle). The effect is sustained at 12 months follow-up (right). Reprinted fxample with a reduction in ischemia is shown in Figure 5. terin et al. (33) presented similar results with stress-rest
c-99m sestamibi SPECT in heart failure patients.
Three studies used intracoronary Doppler with 2 of 3
tudies showing an improvement in coronary flow reserve.
or example, a substudy of the TOPCARE-AMI (Trans-
lantation of Progenitor Cells and Regeneration Enhance-
ent in Acute Myocardial Infarction) trial revealed that
rogenitor cell therapy was associated with complete
estoration of coronary flow reserve due to a substantial
mprovement of maximal coronary vascular conductance
apacity (15).
nfarct size. In the clinical setting, 12 studies (including
55 patients) evaluated the effect of cell therapy on infarct
ize (Table 5). Seven studies were performed in the setting
f acute infarction, whereas 5 were performed in patients
ith chronic infarction. Assessment of scar tissue was
erformed ranging from 3 to 18 months after therapy. A
ariety of techniques is available to assess infarct size,
ncluding techniques that directly visualize the scar tissue
i.e., nuclear imaging with PET or SPECT, contrast-
nhanced MRI, myocardial contrast echocardiography), or
ndirect approaches that visualize the extent and severity of
V dysfunction (LV angiography, 2-dimensional echocar-
iography, or cine MRI). Eight studies evaluated infarct
ize with SPECT or contrast-enhanced MRI, whereas 4
tudies evaluated systolic dysfunction in the infarct zone as
n indicator of extent of scar tissue. Seven of 12 studies
emonstrated some reduction in infarct size, both in the
etting of acute and chronic infarction.
The most accurate technique is contrast-enhanced MRI,
llowing precise detection of scar tissue and currently the
nly technique discriminating between subendocardial and
e and 3 and 12 Months After Cell Therapy
f a patient with stress-induced ischemia in the inferolateral myocardium at base-
d mononuclear cells there is a reduction in the extent of stress-induced isch-
eres et al. (31), with permission.aselin
aps o
-derive
rom Beransmural infarction (57). In the BOOST trial, contrast-
Effect of Cell Therapy on Infarct Size
Table 5 Effect of Cell Therapy on Infarct Size
Study No. of Patients Setting/Study Design
Route of
Delivery Cell Type
Follow-Up
(Months) Main Findings Technique Used
Strauer et al. (10) 10 vs. 10 control subjects AMI/observational, control  Intracoronary 2.8  107 BMC 3 2 Infarct size (% of dysfunctional segments) LV angiography
TOPCARE-AMI (11–14) 29 BMC AMI/observational, control  Intracoronary 2.1  108 BMC 12 2 Infarct size (contrast-enhanced volume) Contrast-enhanced MRI
30 CPC 1.6  107 CPC
BOOST (16,17) 30 vs. 30 control subjects AMI/randomized, sham  Intracoronary 2.4  109 BMC 18  Infarct size (contrast-enhanced volume) Contrast-enhanced MRI
Fernández-Avilés et al. (18) 20 vs. 13 control subjects AMI/observational, control  Intracoronary 7.8  107 BMC 6 2 Infarct size (number of dysfunctional
segments)
Cine MRI
Chen et al. (19) 34 vs. 35 control subjects AMI/randomized, sham  Intracoronary 4.8–6.0  1010 BMC 6 2 Infarct size (% of dysfunctional segments) LV angiography
Janssens et al. (21) 33 vs. 34 control subjects AMI/randomized, control  Intracornary 4.8  108 BMC 4 2 Infarct size (contrast-enhanced volume) Contrast-enhanced MRI
ASTAMI (23) 50 vs. 50 control subjects AMI/randomized, sham  Intracoronary 6.8  107 BMC 6  Infarct size (contrast-enhanced volume/
number of scar segments)
Contrast-enhanced MRI
Tc-99m tetrofosmin
SPECT
TOPCARE-CHD (24) 28 BMC vs. 24 CPC vs. 23
control subjects
CMI/randomized, sham  Intracoronary 2.1  108 BMC
2.2  107 CPC
3  Infarct size (contrast-enhanced volume) Contrast-enhanced MRI
IACT (25) 18 vs. 18 control subjects CMI/observational, control  Intracoronary 9  107 BMC 3 2 Infarct size (extent of dysfunctional area) LV angiography
Katritsis et al. (26) 11 vs. 11 control subjects CMI/observational, control  Intracoronary 2–4  106 BMC and EPC 4 2 Infarct size (number of scar segments) Tc-99m sestamibi
SPECT
Beeres et al. (29–31) 25 AP/observational, control  Intramyocardial 8.4  107 BMC 3  Infarct size (contrast-enhanced volume) Contrast-enhanced MRI
Erbs et al. (34) 13 vs. 13 control subjects CTO/randomized, sham  Intracoronary 6.9  107G-CSF–
mobilized cells
3  Infarct size (contrast-enhanced volume) Contrast-enhanced MRI
Abbreviations as in Tables 3 and 4.
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Imaging of Stem Cell Therapy March 20, 2007:1137–48nhanced MRI was performed at baseline, at 6 and 18
onths follow-up. At 18 months, a mean reduction in
nfarct size of 13  12 ml was demonstrated in patients
ndergoing cell therapy, but control patients exhibited a
omparable reduction in infarct size (10  13 ml; p  NS
s. patients undergoing cell therapy) (17). Of note, Ing-
anisorn et al. (58) recently demonstrated a significant
eduction in infarct size on contrast-enhanced MRI per-
ormed at 1.7  0.8 days and 2 months after acute
yocardial infarction. Clearly, randomized controlled trials
re needed to evaluate changes in infarct size after cell
herapy as compared with the natural evolution after reper-
used acute infarction.
yocardial viability. A total of 10 studies (in 243 patients)
valuated changes in viability after cell therapy (Table 6).
ix studies were performed in the setting of acute infarction,
studies after chronic infarction, and 2 studies in patients
ith stress-induced ischemia. Follow-up ranged from 3 to 6
onths after cell therapy.
The clinically available techniques for evaluation of via-
ility include nuclear imaging with PET (mainly using
18-FDG, evaluating glucose utilization) or SPECT (with
18-FDG or Tc-99m–labeled agents), or low-dose dobu-
amine echocardiography (assessing contractile reserve).
ontractile reserve can also be assessed by low-dose dobu-
amine MRI. Non-fluoroscopic catheter-based electro-
echanical mapping enables identification and localization
f viable myocardial tissue by simultaneous assessment of
lectrical activation and local mechanical response.
Five studies used F18-FDG PET or SPECT to evaluate
iability in the infarct zone of which 4 reported an increased
18-FDG uptake after cell therapy. For example, in the
ACT (Regeneration of Human Infarcted Heart Muscle by
ntracoronary Autologous Bone Marrow Cell Transplanta-
ion in Chronic Coronary Artery Disease) study, a mean
ncrease of 15% in F18-FDG uptake in the infarct zone was
emonstrated (25). Similarly, in the TOPCARE-AMI
tudy, mean F18-FDG uptake in the infarct zone increased
rom 55% to 58% at 4 months; however, data on control
atients were not available (14).
Three studies used low-dose dobutamine echocardiogra-
hy with 2 of 3 studies showing no improvement in
ontractile reserve, in contrast with the improvement ob-
erved in viability studies using F18-FDG PET. It should
e noted that F18-FDG imaging reflects glucose utilization,
hereas low-dose dobutamine echocardiography detects
ontractile reserve. Although both parameters are markers
f myocardial viability, not all viable myocardium may
xhibit both contractile reserve and preserved glucose utili-
ation. In patients with severely dysfunctional myocardium
nd extensive damage on the cellular level, contractile
eserve is frequently lost, whereas glucose utilization is
reserved (59). Additional studies, evaluating different
eatures of viable myocardium in the same patients, are
eeded to elucidate changes in myocardial viability after cell
herapy. Ef
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March 20, 2007:1137–48 Imaging of Stem Cell Therapyonclusions
he introduction of stem cell therapy for treatment of cell
eath-related heart diseases is promising, but many issues
emain unanswered, including mechanisms of benefit. Both
reclinical and clinical studies have used noninvasive imag-
ng techniques for in vivo tracking of stem cells and
easurement of effect of therapy. For tracking, direct
abeling of cells with radionuclides and super-paramagnetic
gents has been reported; in addition, proof of concept of
he use of reporter genes for cell tracking has been
emonstrated. However, the majority of the methods
vailable for cell tracking are currently only used in
nimal model studies.
In the clinical setting, various imaging techniques includ-
ng MRI, nuclear imaging with PET and SPECT, and
chocardiography have been used to assess functional effects
f cell therapy. Initial studies using these imaging tech-
iques have mostly reported an improvement in LV func-
ion and myocardial perfusion/viability, with a reduction in
nfarct size. However, the evidence is limited, and double-
lind, randomized, controlled trials with concurrent imag-
ng techniques are needed to confirm and further elucidate
eneficial effects of cell-based therapies. Moreover, future
tudies will need to assess the reproducibility and accuracy
f the imaging methods used for cell tracking and evaluation
f the functional effects. Finally, imaging on the molecular
evel is needed to better understand the effects of cell
herapy. This will be realized with the use of PET-CT (or
PECT-CT), which permits co-registration of anatomical
CT) and functional (PET, SPECT) information, and also
ith 3-T (and higher) MRI.
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